REG - Immupharma PLC - Response to Share Price Movement

ImmuPharmaAnnouncement

28/01/2025 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250128:nRSb9943Ua&default-theme=true

RNS Number : 9943U  Immupharma PLC  28 January 2025

 

28 January 2025

ImmuPharma PLC

("ImmuPharma" or the "Company")

Response to Share Price Movement

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, notes the recent movements in its share price.

As announced on 9 January 2025, the Company has made innovative groundbreaking
advancements in its preclinical research program focused on P140 and the
pathogenesis of autoimmune diseases. This new discovery, conducted by the
Company's R&D subsidiary ImmuPharma Biotech, has yielded data that
provides novel insights into autoimmune disease mechanisms. Through this
research, the Company is making a significant step towards personalised
medicine in SLE and other autoimmune diseases.

(Link: https://www.immupharma.co.uk/news/ (https://www.immupharma.co.uk/news/)
)

The ImmuPharma team also attended the JP Morgan and Biotech Showcase
healthcare conferences earlier this month.

Attending both meetings gave the ImmuPharma team the opportunity to continue
positive discussions with a number of global BioPharma companies, that have
already expressed an interest in P140 and its unique approach to treating
autoimmune diseases.

ImmuPharma is not aware of any further material commercial or operational
reason for the significant share price movements, however, the Company will
continue to update the market on developments, both commercially and
scientifically, when appropriate, over the next period.

End

 

 

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk (http://www.immupharma.co.uk) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                             + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                               +44 (0) 203 368 3550 (about:blank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                              +44 (0) 20 3650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                             +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

 About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140, is a unique non-immunosuppressive
peptide for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP
(Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models
suggest therapeutic activity for many other autoimmune diseases.

 

 

For additional information about ImmuPharma please visit www.immupharma.co.uk
(http://www.immupharma.co.uk/)

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  SPMBDGDBLUDDGUI